A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose or Multiple Ascending Dose Study of KK4277 in Healthy Volunteers, Patient With Systemic Lupus Erythematosus, and Patient With Cutaneous Lupus Erythematosus
Latest Information Update: 26 Sep 2024
At a glance
Most Recent Events
- 19 Sep 2024 Planned number of patients changed from 116 to 157.
- 19 Sep 2024 Planned End Date changed from 1 Mar 2025 to 1 Dec 2025.
- 06 Aug 2023 Planned End Date changed from 1 Sep 2024 to 1 Mar 2025.